Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-specific CD4+ memory T cell responses

Journal of Infectious Diseases

Volumn 202, Issue 8, 2010, Pages 1200-1211

  Van Den Hende, Muriel ^a   Redeker, Anke ^a   Kwappenberg, Kitty M C ^a   Franken, Kees L M C ^a   Drijfhout, Jan W ^a   Oostendorp, Jaap ^a   Valentijn, A Rob P M ^a   Fathers, Loraine M ^a   Welters, Marij J P ^a   Melief, Cornelis J M ^a   Kenter, Gemma G ^a   Van Der Burg, Sjoerd H ^a   Offringa, Rienk ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; HERPES VACCINE; ONCOPROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD4[+] T LYMPHOCYTE; CELL CULTURE; CLADISTICS; CLINICAL ARTICLE; CROSS REACTION; DISSECTION; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNITY; IMMUNOREACTIVITY; LYMPHOCYTE CULTURE; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; WART VIRUS; ALPHAPAPILLOMAVIRUS; CELL LINE; IMMUNOLOGY;

ALPHAPAPILLOMAVIRUS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL;

EID: 77957011169     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656367     Document Type: Article

References (24)

1. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64:5449-455.
2. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62:472-479.
3. van Poelgeest MI, Nijhuis ER, Kwappenberg KM et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006; 118:675-683.
4. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63:636-641.
5. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996; 65:768-773.
6. Kenter GG, Welters MJ, Valentijn AR, et al. Vacination against HPV16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-1847.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527. (Pubitemid 36159887)
8. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005; 32(Suppl 1):S1-S6.
9. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995; 69:3074-3083.
10. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur HH. Classification of papillomaviruses. Virology 2004; 324:17-27.
11. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-632. (Pubitemid 46986496)
12. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626-1636.
13. + T cells by at least four unrelated HLA-DR molecules. J Immunol 1999; 162:152-160.
14. van der Burg SH, Ressing ME, Kwappenberg KM, et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91:612-618.
15. Franken KL, Hiemstra HS, van Meijgaarden KE, et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 2000;18:95-99.
16. de Jong A, van der Hulst JM, Kenter GG, et al. Rapid enrichment of human papillomavirus (HPV) - specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 2005; 114:274-282.
17. + T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118:950-956.
18. + regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007; 104:12087-12092.
19. + and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-187.
20. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182:1097-1102.
21. Woo YL, van den HM, Sterling JC, et al. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer 2010; 126(1):133-141.
22. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-998. (Pubitemid 41323035)
23. Britten CM, Gouttefangeas C, Welters MJ, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57:289-302. (Pubitemid 350295380)
24. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-3402.